Compare SURG & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SURG | PMN |
|---|---|---|
| Founded | 2006 | 2004 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Advertising | Pharmaceuticals and Biotechnology |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 47.6M | 23.5M |
| IPO Year | N/A | N/A |
| Metric | SURG | PMN |
|---|---|---|
| Price | $1.71 | $9.42 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $9.50 | ★ $72.67 |
| AVG Volume (30 Days) | ★ 109.5K | 43.4K |
| Earning Date | 11-12-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $50,372,555.00 | N/A |
| Revenue This Year | $7.13 | N/A |
| Revenue Next Year | $122.51 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.05 | $6.27 |
| 52 Week High | $3.47 | $39.75 |
| Indicator | SURG | PMN |
|---|---|---|
| Relative Strength Index (RSI) | 40.50 | 82.78 |
| Support Level | $1.40 | $7.35 |
| Resistance Level | $1.90 | $9.42 |
| Average True Range (ATR) | 0.16 | 0.68 |
| MACD | 0.02 | 0.18 |
| Stochastic Oscillator | 50.78 | 84.44 |
Surgepays Inc is a fintech company focused on the underbanked community. It provides services to financial technology, telecommunications, and digital media companies. Its operating segment includes Mobile Virtual Network Operators that provide mobile broadband (internet connectivity), voice and SMS text messaging to both subsidized and direct retail prepaid customers through SurgePhone Wireless, LLC and Torch Wireless, LLC; Comprehensive Platform Services provide financial technology and a wireless top-up platform to independently owned convenience stores throughout the country; and Others. It generates the majority of its revenue from the Mobile Virtual Network Operators segment.
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.